• SvenskaSvenska
Active Biotech
  • Home
  • About
    • Active Biotech in Brief
    • Board of Directors
    • Management
    • Business Concept
    • Corporate Governance
      • Corporate Governance Report 2019
      • Article of Association
      • Audit committee
      • Scientific committee
      • Election Committee
      • General Meetings
      • Auditors
    • Partnerships
    • Career
  • Projects
    • Project Overview
    • Naptumomab
    • Tasquinimod
    • Laquinimod
    • Patents
    • Orphan Drug Designation
  • Investor
    • Investor
    • Analyst coverage
    • Financial Calendar
    • Financial Reports
      • Interim Reports
      • Annual Reports
    • Stock
    • Ownership
    • Official Documents
      • Rights Issue 2014
      • Rights Issue 2016
      • Rights Issue 2018
      • Rights Issue 2021
  • Media
    • Press Contact
    • Press Releases
      • Subscribe
    • News
    • Company Presentation
    • Image Bank
  • Contact
Copyright © 2021 Active Biotech AB. All Rights Reserved.
Design by Clavis Communications.

Media

  • Press Contact
  • Press Releases
    • Subscribe
  • News
  • Company Presentation
  • Image Bank

Press Releases

  • Extraordinary General Meeting of Active Biotech AB (publ)
    December 1, 2014 18:11 (CET)
  • Active Biotech AB: Notice of Extraordinary General Meeting of Shareholders
    November 5, 2014 08:35 (CET)
  • Active Biotech AB Interim report January - September 2014
    November 5, 2014 08:34 (CET)
  • Active Biotech AB: Notice of Extraordinary General Meeting of Shareholders
    November 5, 2014 08:32 (CET)
  • Active Biotech strengthens its financial position: rights issue of approximately SEK 225 million
    November 5, 2014 08:31 (CET)
  • Active Biotech AB Interim report January - September 2014
    November 5, 2014 08:30 (CET)
  • Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
    November 4, 2014 14:00 (CET)
  • Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
    September 12, 2014 14:00 (CEST)
  • Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease
    August 14, 2014 08:36 (CEST)
  • Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease
    August 14, 2014 08:30 (CEST)
  • <
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • >

Content

  • Home
  • About
  • Projects
  • Investor
  • Media
  • Contact

Postal Address

Active Biotech AB
P.O. Box 724
SE-220 07 Lund
Sweden

Visiting Address

Active Biotech AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

+46 46 19 20 00
info@activebiotech.com

LinkedIn

Copyright © 2021 Active Biotech AB. All Rights Reserved.
Design by Clavis Communications.
This site uses cookies.